Sanofi GCC in Hyderabad Boosts India’s Life Sciences Hub

French Pharma Leader Sanofi Doubles Down on Hyderabad, Eyes 1,600 New Jobs by 2026

Hyderabad: French pharmaceutical giant Sanofi is ramping up its Global Capability Centre (GCC) in Hyderabad with bold plans to further expand the workforce, investing heavily in technology and strengthening its digital capabilities.

Set up in 2019, Sanofi’s Hyderabad hub has already become its largest, offering critical services across commercial, R&D, manufacturing, supply chain, and digital functions far beyond its initial mandate as a medical centre.

💊 Who is Sanofi?

Founded in 1973 and headquartered in Paris, France, Sanofi S.A. is one of the world’s largest healthcare companies, with a strong presence in biopharma, vaccines, rare diseases, and consumer healthcare. It employs more than 90,000 people across 100 countries, generating revenues of €43 billion in 2023.

Sanofi is the world’s third-largest vaccine manufacturer through its unit Sanofi Pasteur, supplying immunization solutions globally. It is also a leader in diabetes care, oncology, cardiovascular medicine, immunology, and neurology, with blockbuster drugs such as Dupixent (immunology), Aubagio (multiple sclerosis), and Lantus (insulin).

In recent years, Sanofi has been repositioning itself as a tech-driven biopharma innovator, committing to become the first AI-powered biopharma company at scale by embedding artificial intelligence, automation, and advanced analytics into its R&D and operations.

Sanofi Investment & Expansion Plan in India

The company is committing €400 million (around ₹3,600 crore) to this expansion by 2030, with €100 million slated for deployment by 2025. Over the next two years, Sanofi plans to ramp up its headcount from approximately 1,000 to 2,600 employees, adding 1,600 jobs by 2026.

Sanofi Tech-Driven Transformation

Executives say the Hyderabad hub will anchor Sanofi’s push toward becoming the first AI-powered biopharma company. Hiring will focus on high-end tech roles such as data scientists, software engineers, and data engineers, bolstering its digital transformation drive.

Madeleine Roach, Sanofi’s EVP of Business Operations, called the Hyderabad site a “transformational hub” that will represent the entire value chain for Sanofi, not just support services.

Sanofi Strategic Significance

The expansion demonstrates Sanofi’s pivot toward global resilience and diversification beyond China. Hyderabad’s deep life sciences ecosystem and vast talent pool make it central to this strategy. The facility will handle critical clinical documentation and collaborate with Sanofi’s global teams across the U.S. and Europe.

India’s GCC Landscape

Sanofi’s investment mirrors the surge in India’s GCC market, which is projected to more than double to $110 billion by 2030. Hyderabad, with over 2,000 life sciences companies and growing pharma-tech clusters, is already being recognized as the Life Sciences Capital of India.

Why It Matters – Sanofi GCC Expansion

• Job Creation: 1,600 new roles by 2026, one of Hyderabad’s largest pharma-tech hiring drives.
• Global Innovation: The GCC cements Sanofi’s transition into an AI-first biopharma leader.
• Strategic Hub: Positions Hyderabad at the heart of Sanofi’s global operations.
• Life Sciences Momentum: Reinforces India’s rise as a global GCC powerhouse.

Read more interesting industry news at ScaleGCC